06.03.16
Aptuit has appointed Henning Steinhagen as executive vice president drug discovery and development, and site-head Verona.
Dr. Steinhagen will focus on the growth of Aptuit as a partner research organization and provider of outsourced services in the early discovery and development space. He joins Aptuit from Grünenthal, a global pharmaceutical company, where he was senior vice president, and head of global drug discovery. His accomplishments included discovery successes in multiple therapeutic areas and establishing multiple research partnerships. Before joining Grünenthal, Dr. Steinhagen served for 7 years at Sanofi-Aventis in positions of increasing responsibility in medicinal chemistry.
"I am delighted that Henning is joining us,” said Jonathan Goldman, chief executive officer, Aptuit. “He brings exceptional experience in science, leadership and partnerships that are needed to advance our growth. His collaborative approach to understanding and delivering unmet needs of our customers makes him ideally suited to lead the Verona senior management team."
Dr. Steinhagen will focus on the growth of Aptuit as a partner research organization and provider of outsourced services in the early discovery and development space. He joins Aptuit from Grünenthal, a global pharmaceutical company, where he was senior vice president, and head of global drug discovery. His accomplishments included discovery successes in multiple therapeutic areas and establishing multiple research partnerships. Before joining Grünenthal, Dr. Steinhagen served for 7 years at Sanofi-Aventis in positions of increasing responsibility in medicinal chemistry.
"I am delighted that Henning is joining us,” said Jonathan Goldman, chief executive officer, Aptuit. “He brings exceptional experience in science, leadership and partnerships that are needed to advance our growth. His collaborative approach to understanding and delivering unmet needs of our customers makes him ideally suited to lead the Verona senior management team."